Specific Inhibition of Hypoxia Inducible Factor 1 Exaggerates Cell Injury Induced by in Vitro Ischemia Through Deteriorating Cellular Redox Environment
Overview
Affiliations
Hypoxia inducible factor 1 (HIF-1) has been suggested to play a critical role in the fate of cells exposed to hypoxic stress. However, the mechanism of HIF-1-regulated cell survival is still not fully understood in ischemic conditions. Redox status is critical for decisions of cell survival, death and differentiation. We investigated the effects of inhibiting HIF-1 on cellular redox status in SH-SY5Y cells exposed to hypoxia or oxygen and glucose deprivation (OGD), coupled with cell death analyses. Our results demonstrated that inhibiting HIF-1alpha expression by HIF-1alpha specific small interfering RNA (siRNA) transfection increased reactive oxygen species generation, and transformed the cells to more oxidizing environments (low GSH/GSSG ratio, low NADPH level) under either hypoxic or OGD exposure. Cell death increased dramatically in the siRNA transfected cells, compared to non-transfected cells after hypoxic/OGD exposures. In contrast, increasing HIF-1alpha expression by desferrioxamine, a metal chelator and hydroxylase inhibitor, induced a more reducing environment (high GSH/GSSG ratio, high NADPH level) and reduced cell death. Further studies showed that HIF-1 regulated not only glucose transporter-1 expression, but also the key enzymes of the pentose phosphate pathway such as glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. These enzymes are important in maintaining cellular redox homeostasis by generating NADPH, the primary reducing agent in cells. Moreover, catalase significantly decreased cell death in the siRNA-transfected cells induced by hypoxia and OGD. These results suggest that maintenance of cellular redox status by HIF-1 protects cells from hypoxia and ischemia mediated injuries.
Sharma V, Singh T CNS Neurol Disord Drug Targets. 2024; 24(3):208-218.
PMID: 39428931 DOI: 10.2174/0118715273324551241008111827.
Kang J, Koh P PLoS One. 2024; 19(5):e0303213.
PMID: 38753710 PMC: 11098415. DOI: 10.1371/journal.pone.0303213.
Microglia at the blood brain barrier in health and disease.
Mayer M, Fischer T Front Cell Neurosci. 2024; 18():1360195.
PMID: 38550920 PMC: 10976855. DOI: 10.3389/fncel.2024.1360195.
Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders.
Sharma D, Khan H, Kumar A, Grewal A, Dua K, Singh T J Neural Transm (Vienna). 2023; 130(12):1523-1535.
PMID: 37740098 DOI: 10.1007/s00702-023-02698-3.
Role of CELF2 in ferroptosis: Potential targets for cancer therapy (Review).
Li J, Xian L, Zhu Z, Wang Y, Zhang W, Zheng R Int J Mol Med. 2023; 52(4).
PMID: 37594127 PMC: 10500222. DOI: 10.3892/ijmm.2023.5291.